Jason E Goetzmann
Overview
Explore the profile of Jason E Goetzmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
101
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang D, Li S, Gessler D, Xie J, Zhong L, Li J, et al.
Mol Ther Methods Clin Dev
. 2018 May;
9:234-246.
PMID: 29766031
Adeno-associated virus (AAV) has provided the gene therapy field with the most powerful gene delivery vector to realize safe, efficacious, and sustainable therapeutic gene expression. Because many clinically relevant properties...
2.
Walsh P, Kurup D, Hasselschwert D, Wirblich C, Goetzmann J, Schnell M
Sci Rep
. 2017 Mar;
7:43339.
PMID: 28277549
Could new oral vaccine technologies protect endangered wildlife against a rising tide of infectious disease? We used captive chimpanzees to test oral delivery of a rabies virus (RABV) vectored vaccine...
3.
Warfield K, Goetzmann J, Biggins J, Kasda M, Unfer R, Vu H, et al.
Proc Natl Acad Sci U S A
. 2014 Jun;
111(24):8873-6.
PMID: 24912183
Infectious disease has only recently been recognized as a major threat to the survival of Endangered chimpanzees and Critically Endangered gorillas in the wild. One potentially powerful tool, vaccination, has...
4.
Masarachia P, Pennypacker B, Pickarski M, Scott K, Wesolowski G, Smith S, et al.
J Bone Miner Res
. 2011 Nov;
27(3):509-23.
PMID: 22113859
Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin K (CatK) currently being developed as a once-weekly treatment for osteoporosis. In this study, we evaluated the effects of ODN...